Michelle Van Name, MD
Cards
About
Research
Publications
2025
Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled Trial.
Turner LV, Sherr JL, Zaharieva DP, Baran J, Hirsch IB, Bode BW, Brown SA, Bzdick S, Church MM, Hansen DW, Kingman R, Laffel LM, Shah VN, Stone S, Vienneau TE, Huyett LM, Dumais B, Ly TT, Riddell MC, Omnipod 5 Exercise Research Group. Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled Trial. Diabetes Care 2025, 48: 1598-1606. PMID: 40680105, DOI: 10.2337/dc25-0141.Peer-Reviewed Original ResearchAssociations of CGM Metrics With Stimulated C-Peptide Measures in Youth With Recent-Onset Type 1 Diabetes.
Neyman A, DiMeglio LA, Bauza C, Buckingham B, Clements MA, Forlenza GP, Sherr JL, Kanapka L, Beck RW, Kollman C, Beasley S, Cobry E, Norlander L, McDonough R, Van Name M, Moran A, CLVer Study Group. Associations of CGM Metrics With Stimulated C-Peptide Measures in Youth With Recent-Onset Type 1 Diabetes. Diabetes Care 2025, 48: 1395-1399. PMID: 40465453, DOI: 10.2337/dc25-0291.Peer-Reviewed Original ResearchExtinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment.
Bensignor M, Hsia D, Van Name M, Jastreboff A, Ryder J. Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment. Diabetes Care 2025 PMID: 40730197, DOI: 10.2337/dci25-0031.Peer-Reviewed Original ResearchBariatric surgeryType 2 diabetesYouth-onset type 2 diabetesObesity treatmentPediatric type 2 diabetesClinically significant weight reductionDiabetes remission rateYouth-onset T2DSignificant weight reductionEffective obesity treatmentWeight reductionRemission rateT2D remissionObesity medicationsPediatric patientsSurgical treatmentTreatment regimenObesity therapyDiabetes treatment regimenDiabetes agentsChildhood obesityInsulin resistanceObesityU.S. FoodInsulin sensitivityPharmacokinetic Properties of Once‐Weekly Insulin Icodec in Children and Adolescents With Type 2 Diabetes
Van Name M, Ásbjörnsdóttir B, Gomes M, Hale P, Udupa K, Vinther S, Wolf R, Ribel-Madsen R. Pharmacokinetic Properties of Once‐Weekly Insulin Icodec in Children and Adolescents With Type 2 Diabetes. Pediatric Diabetes 2025, 2025 DOI: 10.1155/pedi/5514927.Peer-Reviewed Original ResearchGeometric mean total exposuresOnce-weekly administrationAdverse eventsType 2 diabetesSingle doseBasal insulinMedian time to maximum concentrationSingle-dose pharmacokinetic profileInsulin icodecPharmacokinetic profilePharmacokinetic propertiesMedian t-maxTime to maximum concentrationSevere adverse eventsInjection site reactionsDosing intervalSite reactionsOnce-weeklyPharmacokinetic analysisInsulin-treatedDays postinjectionSubcutaneous injectionHyperglycemic episodesMaximum concentrationIcodec
2024
Type 1 Diabetes in Children and Adolescents
Hu P, Van Name M, Stephenson K, Sikes K, Tamborlane W. Type 1 Diabetes in Children and Adolescents. 2024, 809-835. DOI: 10.1007/978-3-031-66296-6_30.BooksType 1 diabetesRelative insufficiency of insulinContinuous glucose monitoringMacrovascular complications of diabetesDevelopment of diabetes-related complicationsComplications of diabetesInsufficiency of insulinAdvanced diabetes technologiesPediatric patientsMetabolic derangementsTherapeutic advancesDiabetes mellitusDiabetes-related complicationsMacrovascular complicationsControl of T1DReal-time continuous glucose monitoringMetabolic controlDiabetesLifelong disorderRelative insufficiencyDaily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity
Barbieri E, Bonet J, Fox D, Nelson R, Nelson M, Nelson L, Fernandez C, Van Name M, Samuels S, Caprio S, Sabati M, Galderisi A, Sherr J, Man C, Santoro N. Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity. Obesity 2024, 33: 116-124. PMID: 39658509, PMCID: PMC11666407, DOI: 10.1002/oby.24175.Peer-Reviewed Original ResearchConceptsIntrahepatic fat contentDaily glucose variabilityLiver proton density fat fractionProton density fat fractionGlucose variabilityInsulin sensitivityOral glucose tolerance testFat fractionInsulin secretionAssociated with insulin resistanceFirst-phase insulin secretionAssociated with 2-h glucoseGlucose tolerance testGlucose standard deviationMagnetic resonance imagingOral minimal modelCoefficient of variationBasal insulin secretionPediatric obesityPostprandial glucoseTolerance testCell sensitivityInsulin resistanceObesityResonance imagingClinical Characteristics of Offspring Born to Parents with Type 2 Diabetes Diagnosed in Youth: Observations from TODAY
Tryggestad J, Kelsey M, Drews K, Zhou S, Chang N, Escaname E, Gidding S, Isganaitis E, McKay S, Shah R, Van Name M. Clinical Characteristics of Offspring Born to Parents with Type 2 Diabetes Diagnosed in Youth: Observations from TODAY. Children 2024, 11: 630. PMID: 38929210, PMCID: PMC11201816, DOI: 10.3390/children11060630.Peer-Reviewed Original ResearchType 2 diabetesDiabetes exposureMarker of overall healthPrimary care providersOffspring of participantsLower household incomeDaily medication useYouth-onset type 2 diabetesSignificant socioeconomic disadvantageParent self-reportCare providersSocioeconomic disadvantageHealth outcomesYears of ageMedication useOverall healthRisk of healthSelf-ReportEducational disparitiesHousehold incomeParent reportFemale participantsHealthParticipantsRates of recidivismSafety and prescribing recommendations for verapamil in newly diagnosed pediatric type 1 diabetes (T1D): The CLVer experience
Ekhlaspour L, Buckingham B, Bauza C, Clements M, Forlenza G, Neyman A, Norlander L, Schamberger M, Sherr J, Bailey R, Beck R, Kollman C, Beasley S, Cobry E, DiMeglio L, Paprocki E, Van Name M, Moran A, Group F. Safety and prescribing recommendations for verapamil in newly diagnosed pediatric type 1 diabetes (T1D): The CLVer experience. Journal Of Clinical & Translational Endocrinology 2024, 36: 100352. PMID: 38860154, PMCID: PMC11163172, DOI: 10.1016/j.jcte.2024.100352.Peer-Reviewed Original ResearchSide effectsDiabetes care teamRate of adverse eventsTreated with placeboLiver function abnormalitiesBeta-cell preservationPediatric type 1 diabetesComplete AV blockObservational extension studyAsymptomatic ECG changesPotential side effectsSide effect monitoringCare teamType 1 diabetesPlacebo groupStudy drugVerapamil doseFull dosageNewly-diagnosedAdverse eventsAV blockDrug doseECG changesStudy endFunctional abnormalitiesReal‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
Samuels S, Chajecki A, Hu P, Kayser M, Weyman K, Pan B, Brown E, Van Name M, Wolf R. Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c. Diabetes Obesity And Metabolism 2024, 26: 1305-1313. PMID: 38229444, DOI: 10.1111/dom.15430.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RAFollow-upType 2 diabetesReceptor agonistsGLP-1RAsDiverse cohort of youthEffects of glucagon-like peptide-1 receptor agonistsBody mass index z-scoreMedian Follow-UpMulticentre retrospective studyReduced insulin doseGLP-1RA treatmentPatients prescribed insulinFollow-up visitAssociated with short-term improvementsPaediatric diabetes centresManagement of type 2 diabetesManagement of T2DMetformin regimenBMI-zMedian HbA1cRetrospective studyDosing frequency
2023
Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity
Galderisi A, Tricò D, Lat J, Samuels S, Weiss R, Van Name M, Pierpont B, Santoro N, Caprio S. Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity. JCI Insight 2023, 8: e165709. PMID: 37847560, PMCID: PMC10721315, DOI: 10.1172/jci.insight.165709.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testΒ-cell functionIncretin effectBeta-cell functionInsulin sensitivityInsulin secretionGlucose levelsCell functionIsoglycemic intravenous glucose infusionGreater insulin sensitivityIntravenous glucose infusionPubertal transitionGlucose tolerance testGLP-17Glucagon suppressionGlucose infusionObesityLongitudinal increaseBaselineOGTTEffect groupGreater increaseLongitudinal trajectoriesSecretionGroup
Clinical Trials
Current Trials
Bionic CF
HIC ID2000038742RolePrincipal InvestigatorPrimary Completion Date11/30/2025Recruiting ParticipantsGenderBothAge14+ yearsPhysiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
HIC ID2000036125RolePrincipal InvestigatorPrimary Completion Date12/31/2024Recruiting ParticipantsMetabolic Changes Induced by a Very Low Carbohydrate Diet in Youth With Type 1 Diabetes
HIC ID2000029479RoleSub InvestigatorPrimary Completion Date11/15/2024Recruiting ParticipantsGenderBothAge12 years - 24 yearsPathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Youth with Obesity
HIC ID2000028731RoleSub InvestigatorPrimary Completion Date08/31/2025Recruiting ParticipantsGenderBothAge12 years - 22 yearsThe Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis
HIC ID1604017607RoleSub InvestigatorPrimary Completion Date05/01/2023Recruiting ParticipantsGenderBothAge12 years - 30 years
Clinical Care
Overview
Michelle Van Name, MD, is a pediatric endocrinologist who specializes in treating children with obesity, type 1 diabetes, and type 2 diabetes. Dr. Van Name was drawn to pediatric medicine because she enjoys teaching children how they can improve their health.
“A lot of teaching goes into working with my patients. We talk about causes and effects and come up with ways to get healthier,” she says, adding that she also discusses the biology behind what is going on. “For all my patients, I try to work with them to identify treatment strategies that will fit into their lives and partner with them and their families to make these a reality that will carry into adulthood.”
Dr. Van Name also treats adolescents who are interested in sleeve gastrectomy, a type of bariatric surgery for weight loss. “In line with recommendations from the American Academy of Pediatrics, our team aims to ensure patients and their families are informed about treatment options, which may include medications or bariatric surgery. Along with patients and their families, our team considers these treatments as part of a comprehensive plan focused on current and future health,” she says.
As an associate professor of pediatrics (endocrinology) at Yale School of Medicine, Dr. Van Name is an active researcher, including work to see if medications approved for adults to treat type 2 diabetes or obesity can be effective in adolescents. Her research also focuses on use of technologies and non-insulin medications for patients with type 1 diabetes.
“I am fortunate to work with a wonderful team at Yale, who have been at the forefront of research leading to improvements to improve the health of young people with diabetes or obesity,” she says.
Clinical Specialties
Fact Sheets
Diabetes: Symptoms, Causes, and Treatments
Learn More on Yale MedicineType 1 Diabetes: Symptoms, Causes, and Treatments
Learn More on Yale MedicineType 2 Diabetes: Symptoms and Treatments
Learn More on Yale MedicineHemoglobin A1C Test
Learn More on Yale Medicine
Yale Medicine News
News
News
- April 22, 2024Source: diaTRIBE
Type 1 on a GLP-1 Drug? Watch for Hypoglycemia and DKA
- March 06, 2024
New Frontiers in Obesity Research at Yale
- November 09, 2023Source: Yale Daily News
Yale researchers reflect on adolescent bariatric surgery
- October 23, 2023Source: Yale Medicine
Prediabetes Is on the Rise—But It Can Be Reversed
Get In Touch
Contacts
Pediatric Endocrinology & Diabetes
P.O. Box 208064
New Haven, CT 06520
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Everyone Michelle Van Name, MD